Mineralys Therapeutics today announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease (CKD), ...
Read moreSe destacan algunos párrafos que muestran lo que están en vía de aportar a las terapias celulares y el status de su proyecto PRS ®, biomedicamento inmunomodulador y antiinflamatorio
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the hal...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reports that full patient recruitment ...
Read moreAelis Farma announced publication of a series of studies describing a new pharmacological class, cannabinoid receptor 1 signaling-specific inhibitors (CB1-SSi), and its first drug candidate, AEF0117, ...
Read morePeptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor Omomyc (OMO-103) with standard of care in metastatic pancreatic...
Read moreHan publicado los resultados positivos del ensayo clínico APRIL de Fase 1b/2a de aptaTargets, que ha evaluado la seguridad y eficacia del innovador fármaco neuroprotector ApTOLL en combinación con ...
Read moreLa polipíldora cardiovascular desarrollada por el Centro Nacional de Investigaciones Cardiovasculares (CNIC) y Ferrer, acaba de ser incluida por la Organización Mundial de la Salud (OMS) en la lista...
Read moreAtogepant is the first oral drug that can be useful for patients with chronic migraine, which makes it easier to access, provides flexibility in drug administration and is easier to store, since injec...
Read moreA study has shown that the combination of chemotherapy and atezolizumab, an antibody that stimulates the immune system’s ability to attack cancer cells, is an effective treatment for lung cancer pat...
Read moreThe Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes a collective investment campaign of up to 2 million on the Capital C...
Read moreThe United States has approved Zurzuvae, the first oral treatment specifically for postpartum depression, based on allopregnanolone, a neurosteroid created by the female sex hormone progesterone.
Read more